Case Report: Large Granular Lymphocyte Leukemia (LGLL)-A Case Series of Challenging Presentations.

CLPD-NK LGL leukemia NK STAT-3 TCR immunosuppression

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2021
Historique:
received: 13 09 2021
accepted: 01 12 2021
entrez: 24 1 2022
pubmed: 25 1 2022
medline: 25 1 2022
Statut: epublish

Résumé

Large granular lymphocyte leukemia (LGLL) represents a rare group of diseases with considerable difficulties in their correct diagnostic workup and therapy. The major challenges lie in their distinction from reactive (including autoimmune) lymphoproliferations. Moreover, monoclonal LGL proliferative diseases are in fact a heterogeneous group of disorders, as recognized by the three subtypes in the current WHO classification. It distinguishes two chronic forms (the focus of this case series), namely T-LGLL and chronic lymphoproliferative disorders of Natural Killer cells (CLPD-NK) as well as aggressive NK-cell leukemia. In the clinical routine, the variable presentations and phenotypes of T-LGLL and CLPD-NK are underappreciated. The relevant differential diagnoses range from benign reactive T-cell expansions to other mature T-cell leukemias to highly aggressive γδ-lymphomas. T-LGLL or CLPD-NK patients suffer from a wide variety of symptoms often including, but not limited to, cytopenias or classical autoimmune phenomena. They receive treatments ranging from mere supportive measures (e.g. antibiotics, growth factors, transfusions) over strategies of immunosuppression up to anti-leukemic therapies. The diagnostic pitfalls range from recognition of the subtle T-cell proliferation, repeated establishment of monoclonality, assignment to a descript immunophenotypic pattern, and interpretations of molecular aberrancies. Here, we report a series of selected cases to represent the spectrum of LGLL. The purpose is to raise awareness among the scientifically or practically interested readers of the wide variety of clinical, immunological, and phenotypic features of the various forms of LGLL, e.g. of T-cell type, including its γδ forms or those of NK-lineage. We highlight the characteristics and courses of four unique cases from two academic centers, including those from a prospective nationwide LGLL registry. Each case of this instructive catalogue serves to transport a key message from the areas of (chronic inflammatory) contexts in which LGLL can arise as well as from the fields of differential diagnostics and of various treatment options. Implications for optimization in these areas are discussed.

Identifiants

pubmed: 35070980
doi: 10.3389/fonc.2021.775313
pmc: PMC8767099
doi:

Types de publication

Case Reports

Langues

eng

Pagination

775313

Informations de copyright

Copyright © 2022 Pflug, Littauer, Beverungen, Sretenovic, Wahnschaffe, Braun, Dechow, Jungherz, Otte, Monecke, Bach, Franke, Schwind, Jentzsch, Platzbecker, Herling and Vucinic.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Am J Blood Res. 2021 Jun 15;11(3):227-237
pubmed: 34322285
Blood Cancer J. 2016 Aug 05;6(8):e455
pubmed: 27494824
J Med Virol. 2021 Oct;93(10):5768-5776
pubmed: 34042195
Blood. 2008 Jan 1;111(1):328-37
pubmed: 17890451
Blood. 1991 Dec 15;78(12):3269-74
pubmed: 1742486
Leuk Lymphoma. 1996 Oct;23(3-4):405-8
pubmed: 9031124
Am J Clin Pathol. 2003 Oct;120(4):626-30
pubmed: 14560574
Hemasphere. 2021 Jun 01;5(6):e573
pubmed: 34095757
Blood. 1996 Apr 1;87(7):3000-6
pubmed: 8639922
Cancer Cell. 2020 Nov 9;38(5):661-671.e2
pubmed: 32997958
Clin Lymphoma Myeloma. 2007 Jul;7(7):475-9
pubmed: 17875238
Haematologica. 2014 Dec;99(12):1826-33
pubmed: 25193965
Br J Haematol. 1995 Jun;90(2):300-7
pubmed: 7540855
Blood. 2021 Jun 10;137(23):3153-3154
pubmed: 34110406
Am Soc Clin Oncol Educ Book. 2018 May 23;38:616-625
pubmed: 30231346
Leukemia. 2020 Apr;34(4):1116-1124
pubmed: 31740810
Blood. 2021 Apr 15;137(15):2001-2009
pubmed: 33657207
Leukemia. 2015 Dec;29(12):2427-9
pubmed: 26449659
Am J Clin Pathol. 2013 Nov;140(5):727-35
pubmed: 24124154
Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113
pubmed: 32920324
N Engl J Med. 2012 May 17;366(20):1905-13
pubmed: 22591296
Blood. 2017 Jun 1;129(22):2971-2979
pubmed: 28360039
Hum Pathol. 2018 Nov;81:96-104
pubmed: 29949739
Leukemia. 2002 Oct;16(10):2129-33
pubmed: 12357367
Blood. 1993 Jul 1;82(1):1-14
pubmed: 8324214
Hematol Oncol. 2010 Sep;28(3):105-17
pubmed: 19645074
Blood. 2013 Aug 29;122(9):1583-6
pubmed: 23869084
Blood. 2017 Mar 2;129(9):1082-1094
pubmed: 28115367
Curr Hematol Malig Rep. 2020 Apr;15(2):103-112
pubmed: 32062772
Oncologist. 2006 Mar;11(3):263-73
pubmed: 16549811
Front Oncol. 2020 Feb 18;10:152
pubmed: 32133291
Blood. 2004 Jul 15;104(2):328-35
pubmed: 15044256
Blood. 2021 Aug 26;138(8):662-673
pubmed: 33786584
Br J Haematol. 1999 Sep;106(4):960-6
pubmed: 10519998
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
J Clin Oncol. 2020 Oct 20;38(30):3538-3546
pubmed: 32795225
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Pediatr Blood Cancer. 2008 Jan;50(1):142-5
pubmed: 16767728
J Natl Compr Canc Netw. 2016 Aug;14(8):939-44
pubmed: 27496109
Blood. 2019 Oct 3;134(14):1132-1143
pubmed: 31292114
Blood. 1994 Sep 1;84(5):1620-7
pubmed: 8068951
Blood. 2021 Jun 10;137(23):3237-3250
pubmed: 33512451
Blood. 2013 May 30;121(22):4541-50
pubmed: 23596048
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Am J Pathol. 2004 Oct;165(4):1117-27
pubmed: 15466379
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Bone Marrow Transplant. 2012 Jul;47(7):952-6
pubmed: 22041849
Eur J Haematol. 2003 Oct;71(4):263-5
pubmed: 12950235
Blood. 2020 Oct 29;136(18):2018-2026
pubmed: 32756940

Auteurs

Natali Pflug (N)

Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.

Annika Littauer (A)

Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.
Department of Internal Medicine, GK Mittelrhein, Koblenz, Germany.

David Beverungen (D)

Clinic of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany.

Aleksandra Sretenovic (A)

Institute of Hematology, Clinical Center of Serbia, Belgrade, Serbia.

Linus Wahnschaffe (L)

Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.

Till Braun (T)

Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.

Annika Dechow (A)

Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.

Dennis Jungherz (D)

Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.

Moritz Otte (M)

Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.

Astrid Monecke (A)

Institute of Pathology, University of Leipzig, Leipzig, Germany.

Enrica Bach (E)

Clinic of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany.

Georg-Nikolaus Franke (GN)

Clinic of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany.

Sebastian Schwind (S)

Clinic of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany.

Madlen Jentzsch (M)

Clinic of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany.

Uwe Platzbecker (U)

Clinic of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany.

Marco Herling (M)

Department I of Internal Medicine and Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany.
Clinic of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany.

Vladan Vucinic (V)

Clinic of Hematology, Cellular Therapy, and Hemostaseology, University of Leipzig, Leipzig, Germany.

Classifications MeSH